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Abstract Members of the CHD protein family play key
roles in gene regulation through ATP-dependent chromatin
remodeling. This is facilitated by chromodomains that bind
histone tails, and by the SWI2/SNF2-like ATPase/helicase
domain that remodels chromatin by moving histones. Chd6
isubiquitouslyexpressedinbothmouseandhuman,withthe
highest levels of expression in the brain. The Chd6 gene
contains 37 exons, of which exons 12-19 encode the highly
conserved ATPase domain. To determine the biological role
of Chd6, we generated mouse lines with a deletion of exon
12. Chd6 without exon 12 is expressed at normal levels in
mice, and Chd6 Exon 12 -/- mice are viable, fertile, and
exhibit no obvious morphological or pathological pheno-
type. Chd6 Exon 12 -/- mice lackcoordination as revealed
by sensorimotor analysis. Further behavioral testing
revealed that the coordination impairment was not due to
muscle weakness or bradykinesia. Histological analysis of
brain morphology revealed no differences between Chd6
Exon 12 -/- mice and wild-type (WT) controls. The loca-
tion of CHD6 on human chromosome 20q12 is overlapped
by the linkage map regions of several human ataxias,
including autosomal recessive infantile cerebellar ataxia
(SCAR6), a nonprogressive cerebrospinal ataxia. The
genomic location, expression pattern, and ataxic phenotype
of Chd6 Exon 12 -/- mice indicate that mutations within
CHD6 may be responsible for one of these ataxias.
Introduction
Dynamic remodeling of the chromatin structure during
DNA replication, repair, recombination, and transcription
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changes and modiﬁcations of DNA-protein interactions.
The position of a nucleosome relative to a given DNA
sequence directly inﬂuences the plasticity of chromatin and
transcription of nearby genes (de la Serna et al. 2006). The
processes of nucleosome sliding and nucleosome dis-
placement are energy dependent and carried out by mem-
bers of the sucrose nonfermenting 2 (SNF2) superfamily of
DNA-dependent ATPase proteins (reviewed in Brown
et al. 2007), which function in large multiprotein chroma-
tin-remodeling complexes.
Chromodomain-Helicase-DNA-binding (CHD) proteins
make up one family of SNF2-like chromatin-remodeling
enzymes. The family name is based upon the distinct
combination of structural domains common to all CHD
enzymes; tandem N-terminal Chromodomains, followed by
a SWI2/SNF2-like Helicase/ATPase domain, and a C-ter-
minal portion with less well characterized DNA-binding
capability (Delmas et al. 1993; reviewed in Hall and
Georgel 2007; Marfella and Imbalzano 2007). The catalytic
SWI2/SNF2-like helicase/ATPase chromatin-remodeling
domain shares sequence similarities with bacterial RecA-
like helicase domains.
The SWI2/SNF2-like ATPase domain contains seven
motifs that are conserved throughout evolution (Eisen et al.
1995; Singleton and Wigley 2002; Thoma et al. 2005).
Motif I was ﬁrst characterized by Walker et al. (1982) and
plays a critical role in the catalytic function of the ATP
binding pocket. Within motif I there are 15 amino acids
that are very highly conserved, 9 of which are 100% con-
served among the 16 SNF2 family members compared here
(Supplementary Fig. 1). Point mutation of key conserved
residues in any of the seven motifs has been shown to
remove function of the domain (Richmond and Peterson
1996). Mutation of the lysine within the 100% conserved
GLGKT sequence of motif I has repeatedly been shown to
result in complete loss of ATPase function of SNF2 family
members (Citterio et al. 1998, 2000; Khavari et al. 1993;
Laurent et al. 1993), including the recent characterization
of Chd8 (Thompson et al. 2008). Several human diseases
are associated with mutations within the SWI2/SNF2-like
ATPase domain, indicating the importance of the ATPase
domain in protein function. Mutations within the ATPase
domain of Cockayne syndrome B protein result in ultra-
violet sensitivity and neurodevelopmental abnormalities
(Citterio et al. 2000), while mutations in the ATRX ATP-
ase domain cause a-thalassemia/mental retardation syn-
drome, X-linked (ATR-X syndrome) (Wada et al. 2000).
There are nine CHD proteins in both human and mouse
genomes [NCBI UaWE, Consensus CDS (CCDS) project
in build for 36.3/37.1, 2008] and they are divided into three
subfamilies based on the presence of other protein domains
(Schuster and Sto ¨ger 2002). Mutations in subfamilies I and
II are associated with developmental defects (Kulkarni
et al. 2008; Williams et al. 2004; Yoshida et al. 2008) and
perinatal lethality in mice (Marfella et al. 2006). Genes
CHD5–CHD9 encode the proteins that make up CHD
subfamily III. Currently, mutations within two CHD genes
from subfamily III are associated with pathology. CHD5 is
a tumor suppressor gene, mutations of which contribute to
neuroblastoma (Bagchi et al. 2007; Fujita et al. 2008;
Thompson et al. 2003; White et al. 2005), while mutations
of CHD7 account for over 60% of individuals affected by
CHARGE syndrome, a complex congenital disorder char-
acterized by developmental malformations of the eye, ear,
heart, and genitals as well as cognitive impairment (Ara-
maki et al. 2006; Pagon et al. 1981; Vissers et al. 2004).
These and related ﬁndings highlight the essential role of
CHD family members in normal neural development and
brain function (Bultman et al. 2000; Picketts et al. 1996;
reviewed in Brown et al. 2007; Hsieh and Gage 2005).
CHD6 (formerly called CHD5) is the founding member
of CHD subfamily III (Schuster and Sto ¨ger 2002). First
identiﬁed based on the highly conserved ATPase domain,
the additional presence of ill-deﬁned domains that make up
the DNA-binding domain distinguished CHD6 from sub-
familiesIandII(Fig. 1a).CHD6isaubiquitouslyexpressed
gene (Lutz et al. 2006; Schuster and Sto ¨ger 2002) and is
particularly abundant in regions of the adult mouse brain,
such as the cerebellum, medulla, globus pallidus, and the
retrohippocampal area (Lein et al. 2007; Su et al. 2004).
CHD6 is a large (2711 amino acids) nuclear protein that
colocalizeswithRNApolymeraseIIduringpreinitiationand
elongation stages of RNA synthesis, suggesting that this
chromatin-remodeling enzyme plays a role in modulating
and facilitating the transcription of target genes, which have
yet to be identiﬁed (Lutz et al. 2006). CHD6 precipitates as
part of a large complex of proteins and has been shown to
function in the phase-two stress response pathway by
interaction with the NFE2 related factor 2 (NRF2) tran-
scription factor to regulate expression of NQO1 (Nioi et al.
2005). We previously demonstrated that CHD6 is a DNA-
dependent ATPase with a functional SNF2/SWI2-like heli-
case/ATPase domain (Lutz et al. 2006).
The biological and physiological importance of CHD6 is
not known. A recent case study of a chromosomal trans-
location between CHD6 and the basic helix-loop-helix
transcription factor 4 (TCF4) gene identiﬁed a phenotype
of mental retardation without Pitt-Hopkins syndrome
characteristics that was attributed to the truncation of
TCF4, but the resulting effect on CHD6 expression and
function was not determined (Kalscheuer et al. 2008).
Several human ataxias have linkage map regions that
encompass the position of CHD6 on chromosome 20q12
(Bennetts et al. 2007; Hertz et al. 2004; Tranebjaerg et al.
2003).
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Chd6 Exon 12 -/- mouse. Because exon 12 encodes a
highly conserved portion of the ATPase domain, it is
expected that this deletion inactivates the ATPase domain,
but this expectation has not been experimentally addressed.
A splice from exon 11–13 is in-frame and the mutant
protein is expressed at normal levels. The homozygous
mutant mice are viable and fertile and have no obvious
phenotype. Behavioral testing revealed that homozygous
Chd6 Exon 12 -/- animals exhibit coordination defects
most consistent with a cerebellar neuron disorder.
Materials and methods
Generation of the mutant ES cells and mice
The conditional deletion of exon 12 of the mouse Chd6
gene utilized a targeting construct that contains an Frt/loxP
ﬂanked neomycin cassette positioned 50 of exon 12, with a
third loxP site inserted 30 to the exon (Fig. 1b). The
integrity of the lox-frt-Chd6-ATPase construct was con-
ﬁrmed by restriction digestion and sequencing of Chd6
exons 11, 12, and 13, including the intron-exon boundaries.
Using standard techniques (Nagy 2003), targeted 129
SvIMJ embryonic stem (ES) cells were generated and
C57BL/6/129 SvIMJ mouse lines were developed from one
correctly targeted ES cell clone. The presence of the tar-
geted allele was identiﬁed by PCR and Southern blot.
Mixed WT mice were derived from homozygous wild-type
littermates of mutant mice and were maintained with
breeding strategies identical to those for the mutant mice by
the intercross of multiple-mating pairs with the appropriate
genotype. For genotyping of animals, genomic DNA was
isolated from mouse tails using the Gentra Puregene kit
(Qiagen, Valencia, CA, USA) followed by phenol-chloro-
form extraction. The derived animals were mated to mice
that express either Cre in the germline (Jax
 Mice, stock
Fig. 1 Generation of a Chd6 Exon 12 -/- mouse line. a Domain
architecture of the Chd6 protein. The SWI2/SNF2 helicase domain
contains seven conserved motifs, including motif I (ATP-binding
region) and Ia (DNA binding), which are encoded by exon 12 of
mChd6. b Gene targeting strategy: A portion of the mChd6 gene
structure is shown, including exons 11-14 (boxes), and the HpaI
restriction enzyme sites used for Southern blot analysis. The targeting
vector ‘‘lox-frt-Chd6-ATPase’’ was designed to enable the deletion of
mChd6 exon 12 by loxP site-speciﬁc recombination. The loxP sites
(white triangles) and direction of transcription of the Neomycin-
resistance gene (Neo) are indicated (arrow). The Frt-ﬂanked Neo-
cassette was removed by ﬂp-mediated, site-speciﬁc recombination
(Frt recombination elements are black triangles). The structure of the
desired allele (D-exon 12) was obtained after Cre-mediated excision
of the ﬂoxed exon 12. The Southern probe and the sizes of HpaI
restriction fragments detected by this probe in wild-type (WT) and
targeted DNA are shown. c Southern analysis of tail clip genomic
DNA: The WT Chd6 allele (3.5 kb band) is distinguishable from the
ﬂoxed conditional Chd6 allele (3.7 kb) and the Chd6 Exon 12 -/-
allele (2.9 kb). d Western analysis: Detection of WT Chd6 (305 kDa)
and mutant D479-558Chd6 (296 kDa) in lung extracts from WT and
Chd6 Exon 12 -/- animals, respectively. The small difference in
molecular weights between WT and mutant Chd6 could not be
detected by this assay
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Exon 12 -/- mice), or ﬂp inthe germline (Jax
Mice, stock
number 003800) to delete the selectable marker but leave
the ATPase domain intact (mixed WT). Deletion of exon 12
was conﬁrmed in genomic DNA by PCR and in the
expressed mRNA by RT-PCR and sequencing of the exon
11-13 junction (data not shown) (see Table 1 for primer
sequences). Mice were either maintained in a mixed genetic
background or backcrossed into the 129SvImJ parental
strain (Jax
 Mice, stock number 002448) until they were
97% 129 genetically (N5), at which point heterozygotes
were crossed to produce the homozygous 129 Exon 12 -/-
line. All mouse work was performed under protocols
approved by the Dartmouth IACUC.
Physiological analysis of mutant mice
Physiological analysis of the mice included observations of
appearance and behavior in the home cage, weight from 3
to 28 weeks of age, the effect of consuming high- and low-
fat diets, and histological analysis of every major tissue and
organ. Samples of each tissue were embedded in parafﬁn
for sectioning and histological analysis of morphology and
cellular structure (see Supplementary Methods for detailed
descriptions). Mice were sacriﬁced by avertin overdose and
whole blood was obtained by cardiac puncture. Blood was
collected either without anticoagulant or into K2 EDTA for
analysis of serum chemistry or complete blood count,
respectively; analysis was performed by Charles River
Laboratories (Wilmington, MA, USA). Protein was iso-
lated from individual tissues and Chd6 Western analysis
was performed as previously described in Lutz et al.
(2006).
Behavioral analysis
For the ledge test, mice were placed on the 0.75 cm edge of
a cage and allowed to either progress along the ledge,
climb down head ﬁrst in a controlled manner, fall off hind
feet ﬁrst in an uncontrolled manner, or sit stationary for up
to 3 min. Collected data were distance traveled if they
moved, or if they did not, the type of descent or whether
they were stationary for the 3 min trial.
Behavioral analysis of age/gender-matched mice began
at 8 weeks of age using mice with known genotypes. Male
and female animals performed equally in all tests so we
interpreted the results based solely on genotype. The data
are represented as the average for all mice of each geno-
type used (Crawley 2007). The mice were put through a
battery of tests in the following order: open ﬁeld maze,
Barnes maze, pole test, and rotorod. Later tests were added,
including wire-hang, beam-walking, and olfactory tests,
which were performed at age 18 weeks or at age 10 weeks.
Age-speciﬁc differences were not observed in the wire-
hang or beam-walking tests between the early and later test
groups so the data were pooled for genotype analysis.
Mice were trained on the accelerating rotorod (model
775, IITC, Woodale, CA, USA) for 2 days and tested for
3 days. The mouse is placed on the rod as it slowly
accelerates and the rotational speed at which the mouse
falls off is recorded. Each trial consisted of the rotorod
accelerating from 1 to 40 rpm over 120 s, with up to 10 s at
40 rpm. Three trials were performed each day for three
consecutive days with a 6 min rest between trials. Mice that
accomplish motor learning will improve in performance
(higher rpm before falling off) with each trial. Mice will
often regress partially for the ﬁrst trial of the following day,
resulting in a stepped pattern. Trials in which mice fell off
the rod when rotating slower than 2 rpm were not included
in the data and the trial was repeated. Detailed methods for
behavioral analysis are provided as supplementary meth-
ods; a detailed chart of the behavioral analysis data is
included as Supplementary Table 1. Statistical analysis
was performed with R software (version 2.5.0;
http://www.r-project.org). Data were analyzed by Welch’s
t test and signiﬁcance was determined as P\0.05.
Table 1 Primers used in the
phenotype assessment of Chd6
Exon 12 -/- mice
Name Primer sequence 50-30 Annealing Tm/product size
Exon 12 -/- foward GACATACACAATGGCATGTATGCT 60C
Exon 12 -/- reverse GTGTACCATCATGCCTGACTCAC 345 bp (-/-), 900 bp (WT)
WT forward ACCCATACTTCTTACCCTCTGCAG 60C
WT reverse GTGTACCATCATGCCTGACTCAC 605 bp (WT)
Exon 11 forward GAAACTGGAGACATCCCGTG 61C
Exon 13 reverse GCAGTTCCTATTCTTCAGTCT 238 bp (-/-), 483 bp (WT)
Nqo1 forward ACAGGTGAGCTGAAGGACTC 57C
Nqo1 reverse CTGCTACGAGCACTCTCTCA 202 bp
b-actin forward GTGGGCCGCTCTAGGCACCA 57C
b-actin reverse CGGTTGGCCTTAGGGTTCAGG 245 bp
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Brains from Chd6 Exon 12 -/- mice and WT controls
were prepared at approximately 17 weeks of age by per-
fusion with 4% paraformaldehyde. Immunohistochemistry
was carried out as previously described using standard
procedures and with antibody dilutions recommended by
the manufacturers (Chakrabarti et al. 2006). Counterstain
of nuclei was achieved using a DAPI type reagent (Hoe-
chst-H stain). Histology with Cresyl violet was performed
on dewaxed sections.
Oxidative stress response analysis
Induction of the stress response pathway followed by
reactive oxygen species challenge was measured by ﬂow
cytometry. Mouse embryonic ﬁbroblast (MEF) cells from
mixed WT and mixed Exon 12 -/- embryos were cultured
and then treated with vehicle control or 1-[2-cyano-3,12-
dioxooleana-1,9(11)-dien-28-oyl]imidazole (CDDO) for
18 h. Cells were harvested and treated with 20,70-dichlor-
odihydroﬂuorescein diacetate (DCFDA) or vehicle for
15 min before addition of tert-butyl hydroperoxide (tBHP)
or vehicle. FACScan (Becton–Dickinson, San Jose, CA)
analysis measured the change in ﬂuorescence intensity.
Stress response stimulation of the Nrf2 pathway was
determined by qPCR analysis of Nqo1 gene expression.
Mixed WT and mixed Exon 12 -/- MEFs cells were
treated with DMSO vehicle control, 5 lM sulforaphane, or
100 nM CDDO for 20 h. RNA was isolated using the
RNeasy kit (Qiagen, Valencia, CA, USA) and reverse
transcribed. Nqo1 and b-actin expression levels were
assayed by iQ SYBER Green PCR (Bio-Rad, Hercules,
CA, USA), with Nqo1 normalized to b-actin expression
(see Table 1 for primer sequences).
Results
Exon 12 -/- mice do not show obvious anatomic
or pathologic phenotype
To test the biological importance of Chd6 we generated a
conditional knockout mouse line that enables the deletion of
Chd6exon12(Fig. 1).Toavoidinterferenceoftheselection
marker with expression of Chd6, the Neomycin resistance
gene was removed by ﬂp-mediated, site-speciﬁc recombi-
nation. Mice with a correctly targeted allele (Targeted) were
crossed with C57BL/6 miceexpressingﬂpinthegermlineto
generatethe conditional(ﬂoxed)allelemice (mixedWT), or
with Cre-expressing BALB/c mice to generate the Exon 12
-/- mice (mixed Exon 12 -/-) (Fig. 1b). Heterozygous
and homozygous targeted mice were identiﬁed through
Southern blotting (Fig. 1c). Deletion of exon 12 removes 81
amino acids of the SWI2/SNF2-like domain which encodes
motif I, a key ATP-binding motif, and motif Ia, which has
DNA-binding activity (Durr et al. 2005). Exon 11 is spliced
in-frame with exon 13 and the Exon 12 -/- protein is
synthesized at WT levels (Fig. 1d).
Exon 12 -/- mice on a mixed C57BL/6/129 Sv/BALB/
c genetic background (mixed Exon 12 -/-) are viable and
fertile and born in normal Mendelian ratios. Mixed Exon
12 -/- mice were compared to mixed lineage mice that
had a ﬂoxed conditional exon 12 allele but did not have the
deletion (mixed WT). Pathological analysis of mixed Exon
12 -/- mice included histological analysis of tissues
(including lung, bone marrow, skin/fat, liver, gastrointes-
tinal tract, spleen/lymph nodes, kidney, pancreas, brain,
heart, thymus, skeletal muscle, and testis or uterus) at two
developmental time points, 26 days or 90 days of age;
there were no differences in any tissue (data not shown).
Whole blood and serum analysis revealed no changes in
complete blood counts or serum chemistry (data not
shown). Analysis of mouse body weight while consuming
both high-fat and low-fat diets identiﬁed no difference
between mixed Exon 12 -/- and mixed WT animals in
body mass and did not indicate any metabolic deﬁciencies
(Supplementary Fig. 2). Mouse embryonic ﬁbroblast
(MEF) cell lines of mixed Exon 12 -/- mice and mixed
WT mice were used to determine that there was no dif-
ference in the DNA repair pathways of the Chd6 Exon 12
-/- mice, and analysis of splenocytes by ﬂow cytometry
(FACScan analysis) indicated that there was no difference
in the cell cycle dynamics (data not shown).
To further determine potential strain-speciﬁc pheno-
types, the Exon 12 -/- line was backcrossed into the
129 SvImJ parental strain until it was 97% pure 129 Sv
statistically (N5 generation), at which point heterozygotes
were crossed to produce homozygous 129 SvImJ Chd6
Exon 12 -/- mice (129 Exon 12 -/-), which were then
compared to pure 129 SvImJ strain (129 WT) from The
Jackson Laboratory (Bar Harbor, ME, USA). 129 Exon 12
-/- mice also exhibit no developmental problems and are
born in expected Mendelian ratios.
Behavioral studies reveal Exon 12 -/- mice have
impaired coordination and balance
The analysis of potential phenotypes included behavioral
studies, as Chd6 is highly expressed in the brain and par-
ticularly in the cerebellum (Lein et al. 2007; Su et al.
2004). Mice from both mixed and 129 Sv genetic back-
grounds displayed no difference in behavior when observed
while in the home cage. However, a preliminary test of
neurological function, the ledge test (Chen et al. 2005),
indicated a coordination deﬁciency.
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along the 0.75 cm-wide ledge of a mouse cage over a
speciﬁed period of time. The mice were scored for move-
ment along the ledge and if they did not progress, they
were scored on whether they sat still for a full 3 min until
removed, fell off the ledge, or made a controlled descent.
Most mixed WT mice progressed (n = 13) with an average
progression of 47 cm compared with the average distance
of 3 cm per mouse observed in mixed Exon 12 -/- mice
(n = 10), most of whom did not progress (Fig. 2a). Of the
mixed WT that did not progress, most climbed into the
cage in a controlled manner head ﬁrst, and a small per-
centage either did not move or fell off the ledge (Fig. 2b).
129 WT (n = 11) and 129 Exon 12 -/- mice (n = 17)
were equally unlikely to progress and there was no dif-
ference between the progression distances in the 129
strains (Fig. 2c). Most of the 129 Exon 12 -/- fell into the
cage and rarely climbed down, while 129 WT generally
either climbed down or sat still and never fell (Fig. 2d).
The ledge test shows that there is a clear difference in the
ability of Exon 12 -/- mice to move on the ledge or
descend in a controlled manner, regardless of the genetic
background. The inability to progress along the ledge or
descend off the ledge in a controlled, head-ﬁrst manner
suggests a deﬁciency in motor coordination in the Exon 12
-/- mice.
Several conditions may result in loss of motor coordi-
nation, including muscle weakness and ataxia (impaired
coordination or balance) (Gowen and Miall 2007). Fol-
lowing the indication of impaired motor coordination,
Exon 12 -/- mice from both mixed lineage and 129 Sv
backgrounds were analyzed with a battery of behavioral
tests, including sensorimotor assays.
The rotorod assay measures motor coordination and,
with repeated trials is able to assay motor learning
(Crawley 2007). The impaired ability of the Exon 12 -/-
mice to run on the rotorod at greater than moderate speeds
is the most obvious and highly signiﬁcant phenotype of the
behavioral testing (P\0.0001). Mixed Exon 12 -/- mice
(n = 21) fell off signiﬁcantly earlier than the mixed WT
controls (n = 21) in every trial (Fig. 3a). This was true for
all three trials run on a given day and for all 3 days of
testing. It was common for the mixed WT mice to reach the
top speed tested on the rotorod (40 rpm) and maintain that
pace, while this was highly unusual for mixed Exon 12
-/- mice. The 129 Exon 12 -/- mice (n = 13) also fell
Fig. 2 Exon 12 -/- mice are impaired in the ledge test compared to
WT mice. Mice were placed on the 0.75 cm-wide ledge of a mouse
cage and observed for 3 min. Mice were scored as having performed
one of four behaviors: remaining stationary on the ledge, falling off
the ledge, climbing into the cage in a controlled manner, or
progressing along the ledge. a Average distance progressed by mixed
lineage WT and Exon 12 -/- mice. b Percent of mixed lineage mice
to perform each behavior. c Average distance crossed by 129 Sv
lineage Exon 12 -/- and WT mice. d Percent of 129 Sv lineage mice
to perform each behavior. Data are represented as a percentage of the
total number of mice tested. Error bars are ±SEM, signiﬁcant
difference is indicated by * (P\0.05 for the same behavior
compared between WT and Exon 12 -/- of the same lineage)
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every trial (Fig. 3b). Interestingly, motor learning was not
affected by the deletion of the Chd6 exon 12. All groups of
mice generally improve the average trial rpm over the three
trials of a given day (Fig. 3a, b). This manifestation of
motor learning is particularly clear for the 129 lineage.
This learning is not fully retained overnight as the ﬁrst trial
of a new day of testing has a lower average than the last
trial of the previous day, but there was some retained motor
learning because often a given day’s averages are higher
than those of previous days. For all trials, the average
maximum rpm that the mixed Exon 12 -/- mice reached
before falling was 19.4 rpm (±2.46 SEM). This is
signiﬁcantly slower than the mixed WT mice, which
averaged 36.6 rpm (±1.68) before falling (Fig. 3c). For all
trials, the average maximum rpm that the 129 Exon 12 -/-
mice reached before falling was 20.51 rpm (±3.19), and
the average for the 129 WT control group was 32.6 rpm
(±2.21) (Fig. 3d).
The lack of coordination seen in both the ledge test and
the rotorod and the high levels of Chd6 present in the
cerebellum (Lein et al. 2007) are indicative of an ataxia
phenotype caused by neural impairment. To determine
whether the impaired coordination of the Exon 12 -/-
mice was due to a progressive ataxia, 129 Exon 12 -/-
mice and 129 WT mice that had previously run the rotorod
apparatus at 10 weeks of age were tested again at 20 weeks
of age. The ability of aged 129 WT mice (n = 9) to run on
the rotorod was diminished (129 WT, 32.6 rpm; aged 129
WT, 26.2 rpm average), and the aged 129 Exon 12 -/-
mice (n = 6) had a slightly reduced performance (129
Exon 12 -/-, 20.5 rpm; aged 129 Exon 12 -/-,
18.9 rpm). The difference in aged 129 WT performance
and aged 129 Exon 12 -/- performance continued to be
signiﬁcant, but it did not increase appreciably (Fig. 3e),
indicating that the ataxia is not strongly progressive
between 10 and 20 weeks of age.
Mice may display impaired ability during the rotorod
assay for several reasons such as poor coordination or
balance, bradykinesis (slowed movement) (Ogawa et al.
1985), increased weight (Cook et al. 2002; McFadyen et al.
2003), or muscular deﬁciencies (Koch et al. 2008). Previ-
ous studies had determined no difference in the weights of
the mice (Supplementary Fig. 2). To investigate the
impaired movement of Chd6 Exon 12 -/- mice, further
behavioral tests were performed.
To determine whether muscle weakness was the cause
of the poor rotorod performance, the wire-hang test was
performed on all lineages (mixed WT, n = 18; mixed Exon
12 -/-, n = 14; 129 WT, n = 12; 129 Exon 12 -/-,
n = 9). The wire-hang test directly measures the ability of
the mouse to hang from a wire grid, reﬂecting muscle
strength (Crawley 2007). Exon 12 -/- mice in both lin-
eages performed as well as their WT counterparts in the
wire-hang test (Fig. 4a, b).
The pole test is used to identify bradykinesis and also is
indicative of muscle strength (Berardelli et al. 2001; Bouet
et al. 2007) and proper dopaminergic neuronal signaling
(Iwamoto et al. 2003; Matsuura et al. 1997). The pole test
determines whether mice placed head up on a thin upright
pole can both successfully invert and travel down the pole.
Mixed Exon 12 -/- mice (n = 20) and 129 Exon 12 -/-
mice (n = 9) were able to invert (Fig. 4c, d) and descend
(Fig. 4e, f) the pole in times similar to those of the mixed
WT (n = 21) and 129 WT mice (n = 12). Results from the
wire-hang and pole tests suggest that the difﬁculty in the
Fig. 3 Exon 12 -/- mice have impaired rotorod performance. Mice
were tested for 3 days, with three trials per day for a total of nine
trials. a Average rpm reached for individual trials with mixed lineage
mice. b Average rpm reached for individual trials with 129 Sv lineage
mice. For both lineages, in each trial the WT results are signiﬁcantly
different from the Exon 12 -/- results (P\0.01). c Average rpm for
all trials with mixed lineage mice. d Average rpm for all trials with
129 Sv lineage mice. e Average rpm for all trials with 129 Sv lineage
mice tested at week 20. Error bars are ±SEM, Signiﬁcance of
P\0.01 is indicated by *
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bradykinesis.
The beam-walking test measures both coordination and
balance by assessing the ability to walk across a tape-
covered cylindrical beam (1.5 cm wide and 61 cm long)
and enter the home cage (Crawley 2007). The mixed Exon
12 -/- mice have impaired beam-walking ability com-
pared with controls. Thirteen of 21 mixed WT mice walked
the beam and successfully entered the home cage, while 1
of 17 mixed Exon 12 -/- mice walked the beam and
entered the home cage (Fig. 4g). Both 129 WT (n = 12)
and 129 Exon 12 -/- (n = 9) mice performed reasonably
well on the beam-walking test (Fig. 4h), though a lower
percentage of 129 mice performed the task compared to
mixed lineage mice.
The majority of the mixed Exon 12 -/- mice did not
fall off while attempting to cross the beam; they jumped off
into the test area from the start location. This could be
because they lack the coordination and balance to cross the
beam or because of an impaired olfactory capacity. The
mixed Exon 12 -/- mice may have been unable to smell
their home cage and thus had no desire to travel along the
beam. However, an olfactory test determined that mixed
Exon 12 -/- mice are able to smell. After an 18 h fast the
mice were given 3 min to ﬁnd a piece of food hidden under
bedding in a clean cage. Five of six mixed Exon 12 -/-
mice found the food, while only two of six of the mixed
WT mice accomplished this (Fig. 4i).
The open-ﬁeld test directly measures the level of anxiety
in the mouse. The test measures the amount of time a
mouse spends in the center of an open ﬁeld compared to
time spent along the wall. Higher anxiety levels are dem-
onstrated by increased time spent near the wall. The mixed
Exon 12 -/- mice (n = 17) displayed slightly increased
anxiety compared with mixed WT (n = 20), with a ratio of
center to wall of 0.144 (±0.035) for the mixed Exon 12
-/- and 0.342 (±0.057) for the mixed WT indicating less
anxiety (Fig. 5a). The mice showed no difference in other
parameters measured by this test, including distance trav-
eled (Fig. 5b) or ambulatory time (Fig. 5c). No difference
was observed between 129 WT and 129 Exon 12 -/- mice
in the open-ﬁeld test (data not shown). An increased level
of anxiety is characteristic of the 129SvImJ mouse strain
(Hagenbuch et al. 2006), and 129 WT and 129 Exon 12
-/- mice exhibited similarly high levels of anxiety in this
test.
To further explore the differences in anxiety levels in
Exon 12 -/- mice, the Barnes maze was used to study
spatial learning ability as well as anxiety levels. The
Barnes maze consists of a bright open circular platform
with 40 holes along the edge, with a dark goal box beneath
one hole into which the mouse can climb down and hide.
Mice with higher anxiety levels will use spatial cues to
learn where the goal box is located and will enter more
quickly to escape the bright platform than less anxious
control mice (Crawley 2008). The results of the Barnes
maze studies indicated that mixed Exon 12 -/- mice
(n = 21) had no deﬁciency in spatial learning, no increase
in anxiety, and there is no impairment in vision compared
Fig. 4 Behavior analysis of Exon 12 -/- mice demonstrates further
evidence that the sensorimotor defect is not due to muscle weakness
or bradykinesis. The average for all trials is indicated for mixed
lineage and 129 Sv lineage mice were tested on the wire hang (a, b),
pole test (c-f), beam walking (g, h), and olfaction (i). Black bars
indicate WT mice values; gray bars indicate Exon 12 -/- mice
values. Error bars are ±SEM. For beam-walking and olfaction test
data, the number of mice to accomplish the task is represented as a
percent of the total number tested. Signiﬁcance of P\0.01 is
indicated by *
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mice entered the goal box compared with only 5 mixed
Exon 12 -/- mice that entered the goal box in the same
number of trials (Fig. 5d). This difference in entering the
goal box was not due to difﬁculty locating the goal; mixed
WT mice located the goal in 68 of 122 total trials, and
mixed Exon 12 -/- mice located the goal in 63 of 122
trials (Fig. 5e). Repeated trials in the Barnes maze mea-
sures spatial learning ability, as mice use visual cues within
the testing room and learn to ﬁnd the goal box faster on
consecutive days. Mice were tested twice each day for
4 days. While the average time it took the mice to ﬁrst ﬁnd
and investigate the goal box was statistically greater in
mixed Exon 12 -/- mice when measured as a function of
the total number of trials (Fig. 5f), mixed Exon 12 -/-
mice and mixed WT mice decreased the amount of time to
ﬁnd the goal over the eight trials (see the change in average
time between trials 1 and 2 compared to 7 and 8, P\0.01
for both WT and Exon 12 -/- mice, Fig. 5g). The mixed
Exon 12 -/- mice were signiﬁcantly slower than mixed
WT mice only during trial 5; this shows that the slow
phenotype is not consistent (Fig. 5g). These data suggest
that the mixed Exon 12 -/- mice were not increasingly
anxious and spatial learning is not impaired. While the
Exon 12 -/- mice were able to ﬁnd the goal as well as
their WT counterparts, they did not enter it as often; this
may be due to the impaired coordination phenotype. The
high level of anxiety observed in 129 Sv lineage mice, both
WT and Exon 12 -/-, during the open-ﬁeld test was also
observed in the Barnes maze test and made it an unpro-
ductive test for 129 strain mice (data not shown).
A variety of neurodegenerative diseases cause ataxia.
Histological analysis of whole brain sections did not reveal
any obvious differences in overall morphology between
WT and Exon 12 -/- animals in either genetic back-
ground (data not shown). Cerebellar defects are frequently
associated with ataxias, so to identify potential structural
changes we histologically analyzed the cerebellum. Nissl
staining was performed to visualize the overall lobe
structure and neuronal arrangement; this appeared to be
Fig. 5 Behavioral analysis of
mixed-lineage Exon 12 -/-
mice indicates normal spatial
learning and mild anxiety.
Mixed-lineage mice were tested
for anxiety in the open-ﬁeld
maze and spatial learning and
anxiety in the Barnes maze.
Open-ﬁeld measurements
included (a) center-to-wall time
ratio, (b) total distance traveled
in centimeters, (c) the amount of
ambulatory time. The Barnes
maze measurements included
(d) the percentage of mice that
entered the goal box, (e) the
percentage of mice ﬁnding and
investigating the goal, (f) the
average time to ﬁnd and
investigate the goal for all trials,
and (g) the average time to ﬁnd
the goal for each trial. For
Barnes maze data, the number
of mice to accomplish the task
is represented as a percent of the
total number tested. Error bars
are ±SEM. Signiﬁcance of
P\0.05 is indicated by *
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mentary Fig. 3a). By immunoﬂuorescence we further
studied the integrity of Purkinje cells and looked for evi-
dence of axonal damage. We did not detect any histological
abnormalities in Exon 12 -/- cerebella and no signs of
neuronal degeneration were apparent (Supplementary
Fig. 3b, c).
Gene regulation by Chd6 is not completely dependent
on exon 12
Chd6 has been shown to play a role in the induction of the
phase-two stress response pathway (Nioi et al. 2005). Loss
of exon 12 is expected to remove the ATPase function of
Chd6, which should inhibit transcription of Chd6 target
genes. To determine if exon 12 of Chd6 plays a critical role
in the phase-two stress response, we stimulated the Nrf2
pathway in mouse embryonic ﬁbroblasts from mixed Exon
12 -/- and mixed WT mice. Treatment of MEF cells with
compounds that stimulate stress response pathways
increased expression of Nqo1 in like manner in Exon 12
-/- mice and WT mice, irrespective of the stimulating
compound used (Fig. 6a). The increased expression of Nrf2
pathway protective genes generated by the pretreatment
with CDDO resulted in more efﬁcient response upon
exposure to reactive oxygen species. The level of protec-
tion, measured as the reduction in ﬂuorescence intensity of
DCFDA upon cell exposure to tBHQ, did not identify
differences in the protective response of Exon 12 -/-
MEFs compared to that of WT (Fig. 6b). These results
indicate that the Chd6 exon 12 is not critical for Chd6
function in the response to oxidative stress.
Discussion
Chd6 Exon 12 -/- mice are ataxic
The studies reported here demonstrate that deletion of the
Chd6 exon 12 causes impaired performances in a variety of
sensorimotor tests, particularly on the rotorod, ledge test,
and balance beam. Several different pathological problems
can contribute to sensorimotor impairment, such as lack of
coordination, poor balance, bradykinesis, or poor muscle
strength. Further behavioral testing indicated that only
coordinationandbalanceareimpairedinChd6Exon12-/-
mice.Thesensorimotordeﬁciencycanbeattributedtoalack
of coordination; therefore, it can be deﬁned as an ataxia
(Gowen and Miall 2007). The ataxia phenotype can be
classiﬁed, based on the affected region of the brain, as a
cerebellar, sensory, vestibular, or optic ataxia. The lack of
coordination is further distinguished as progressive or non-
progressivebywhethertheataxiagetsmoreseverewithage.
Many mutations that cause cerebellum degeneration result
inanataxicphenotype(Chakrabartietal.2008;Cheronetal.
2008; Dusart et al. 2006; Harkins and Fox 2002; Millen and
Gleeson2008). Theataxiaof Chd6 Exon12-/-mice isnot
noticeably progressive and does not change signiﬁcantly
with age. Combined, our results demonstrate a deﬁciency in
the coordination and balance of Chd6 Exon 12 -/- mice
that most likely represents cerebellar ataxia.
While the cerebellum is responsible for many functions
in the brain, including sensory perception, the olfactory test
demonstrated that mixed Exon 12 -/- mice detect odor
with normal efﬁciency, and the improved spatial learning
demonstrated in the Barnes maze suggests that vision is not
impaired. Morphological analysis of the brain determined
that the apparent cerebellar impairment is not due to visible
malformation or cell structure deﬁciencies, indicating that
the ATPase domain of Chd6 is not a dominant factor in the
regulation of genes necessary for cerebellar development
Fig. 6 Stimulation of the Nrf2 stress response pathway does not
require the Chd6 exon 12. a Treatment of MEF cells with Nrf2
pathway stimulants CDDO or Sulforaphane increased the expression
of Nqo1 in Exon 12 -/- MEF cells and WT MEFs to similar levels.
qPCR analysis of the level of Nqo1 normalized to b-actin expression
levels. b Increased expression of Nrf2 target genes results in
protection from ROS challenge at similar levels in Exon 12 -/-
MEF cells and WT MEF cells. MEFs pretreated with control or
CDDO were labeled with DCFDA and challenged with tBHQ. The
level of DCFDA ﬂuorescence was measured by FACScan, and the
change in mean ﬂuorescence intensity was measured as treated over
untreated levels. The average of six experiments is shown
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123and survival. Despite a lack of immunohistochemical evi-
dence for cerebellar dysfunction in our current study, there
is a distinct possibility that subcellular changes may affect
cerebellar signaling and function as a result of exon 12
deletion altering Chd6 target gene expression levels.
CHD6 is a candidate gene for human recessive ataxias
In recent years two human ataxia mutations were mapped
to regions that contain 20q12, the site of CHD6. Autosomal
recessive infantile cerebellar ataxia (SCAR6 or CL3)i sa
nonprogressive ataxia that has been mapped to a 19.5-Mb
region on chromosome 20q11-13 (Bennetts et al. 2007;
Tranebjaerg et al. 2003), a region that contains many
genes, including CHD6. A balanced translocation with
resulting ataxia has breakage points that map proximal to
CHD6 (Hertz et al. 2004). A translocation between CHD6
and TCF4 interrupts CHD6 between exon 1 and exon 2,
and the resulting phenotype has been attributed to the
truncation of the TCF4 gene (Kalscheuer et al. 2008). The
phenotype observed in the Chd6 Exon 12 -/- mice makes
the human CHD6 gene a promising candidate gene for the
mutations that cause one or both of the ataxias, and sug-
gests that the phenotype of the translocation patient may
have multiple causes.
What little is known about Chd6 suggests its role as a
chromatin-remodeling protein that interacts with several
partners (Lutz et al. 2006). These partners include tran-
scription factor NRF2 of the stress response pathway, and
its target gene NQO1.(Nioi et al. 2005). Loss of exon 12 is
expected to remove ATPase activity from Chd6, which in
turn may affect transcriptional regulation of Chd6 target
genes. To determine whether loss of exon 12 affects the
Chd6/Nrf2 interaction, we assayed the stress response
signaling pathway in mouse embryonic ﬁbroblasts using
two different techniques for activating the stress response
pathway; however, there was no signiﬁcant difference in
either test suggesting that exon 12 is not necessary for the
role Chd6 plays in regulation of the Nrf2 stress response
pathway. The difference between our results and those of
Nioi et al. (2005) could have a number of explanations. The
functional interaction of CHD6 and NRF2 in regulating
stress response genes in human cells was acting on the
pathway in a dominant negative manner. It is possible that
the ATPase domain is not required for the functional
involvement of Chd6 in the pathway. And ﬁnally, it is
possible that the pathways do not function identically in a
speciﬁc human cancer cell line (Hela), as studied by Nioi
et al., and in primary mouse cells, as studied here.
Although Chd6 is expressed ubiquitously, the only con-
sistent phenotype appears to be the impairment in sensori-
motor performance. The hypothesis that initiated these
studies was that chromatin remodeling by the ATPase
domain was the central function of Chd6. Based on the
compiled biochemical analyses of mutations within the
highly conserved motif I of the ATPase domain (Richmond
and Peterson 1996), the deletion of exon 12 eliminates the
ability of Chd6 to utilize ATP in the process of chromatin
remodeling. The phenotype of the Chd6 Exon 12 -/- mice
may not include all the potential phenotypes of a full Chd6
null mutation. CHD proteins are large proteins that work as
part of multisubunit complexes. There are several other
domains within Chd6 that may have ATPase-independent
functional activity, in particular, the DNA-binding domain;
the BRK domain (also called TCH), the function of which is
notclearlyunderstood(Allenetal.2007;Doerksetal.2002);
and the SANT domain, which binds to histone N-terminal
domains(Aaslandetal.1996;Boyeretal.2002,2004).Chd6
may act as a ‘‘scaffold’’ protein in complexes containing
other ATPase proteins. The Drosophila CHD6 homolog,
kismet-L, colocalizes with chd1 at sites of transcription ini-
tiation but does not colocalize with chd1 after promoter
clearance by Pol II (which is indicated by the phosphoryla-
tion of the Pol II C-terminal domain serine 5) when active
transcription is occurring (Srinivasan et al. 2005). The
potential for CHD6 to bind to other ATPases suggests that
theATPaseactivityofitsbindingpartnerscouldcompensate
forthelackofATPaseactivityintheexon12deletionmutant
described here, while the remaining domains of CHD6
contribute their usual activity. A third possible explanation
for the subtle phenotype observed is the potential for
redundancy in the chromatin-remodeling pathways. Finally,
itispossible,thoughunlikely,thatthedeletionofexon12has
in fact destroyed all the functionality of Chd6. A role in
improvingcoordinationhasobviousselectiveadvantageand
could be the primary contribution of the Chd6 protein.
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